{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:55:27Z","timestamp":1776329727588,"version":"3.50.1"},"reference-count":33,"publisher":"Baskent University","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.6002\/ect.2017.0065","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T01:40:54Z","timestamp":1512524454000},"page":"196-201","source":"Crossref","is-referenced-by-count":3,"title":["Alemtuzumab Induction Is Associated With an Equalization of Outcomes Between White and African American Kidney Transplant Recipients"],"prefix":"10.6002","volume":"17","author":[{"name":"the College of Medicine and Health Sciences, University of Toledo College of Medicine and Health Sciences, Toledo, Ohio, USA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph T.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Mitro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"DeLeonibus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weikai","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munier","family":"Nazzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"issue":"12","key":"ref0","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/TP.0b013e3181fecfcb","article-title":"Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data","volume":"90","author":"Cai","year":"2010","unstructured":"1.\tCai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010;90(12):1511-1515.","journal-title":"Transplantation"},{"key":"ref1","unstructured":"1. OPTN. OPTN\/SRTR annual report: transplant data 1998-2007. 2008; http:\/\/optn.transplant.hrsa.gov\/ar2008."},{"issue":"20","key":"ref2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","unstructured":"3.\tHanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909-1919.","journal-title":"N Engl J Med"},{"issue":"10","key":"ref3","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/00007890-199911270-00032","article-title":"Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients","volume":"68","author":"Calne","year":"1999","unstructured":"4.\tCalne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999;68(10):1613-1616.","journal-title":"Transplantation"},{"issue":"4","key":"ref4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.surg.2004.06.015","article-title":"Campath-1H in renal transplantation: The University of Wisconsin experience","volume":"136","author":"Knechtle","year":"2004","unstructured":"5.\tKnechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery. 2004;136(4):754-760.","journal-title":"Surgery"},{"issue":"10","key":"ref5","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1111\/j.1600-6143.2005.01067.x","article-title":"Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results","volume":"5","author":"Kaufman","year":"2005","unstructured":"6.\tKaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. Am J Transplant. 2005;5(10):2539-2548.","journal-title":"Am J Transplant"},{"issue":"7","key":"ref6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial","volume":"8","author":"Margreiter","year":"2008","unstructured":"7.\tMargreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant. 2008;8(7):1480-1485.","journal-title":"Am J Transplant"},{"issue":"9117","key":"ref7","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/S0140-6736(05)77739-4","article-title":"Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients","volume":"351","author":"Calne","year":"1998","unstructured":"8.\tCalne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet. 1998;351(9117):1701-1702.","journal-title":"Lancet"},{"issue":"20","key":"ref8","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMe1103002","article-title":"Alemtuzumab in kidney-transplant recipients","volume":"364","author":"JF","year":"2011","unstructured":"9.\tMarkmann JF, Fishman JA. Alemtuzumab in kidney-transplant recipients. N Engl J Med. 2011;364(20):1968-1969.","journal-title":"N Engl J Med"},{"issue":"19","key":"ref9","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"DC","year":"2006","unstructured":"10.\tBrennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967-1977.","journal-title":"N Engl J Med"},{"issue":"11","key":"ref10","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1111\/j.1600-6143.2005.01090.x","article-title":"Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression","volume":"5","author":"Woodle","year":"2005","unstructured":"11.\tWoodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant. 2005;5(11):2740-2744.","journal-title":"Am J Transplant"},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00007890-199201000-00007","article-title":"Withdrawal of steroids after renal transplantation--clinical predictors of outcome","volume":"53","author":"Hricik","year":"1992","unstructured":"12.\tHricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation--clinical predictors of outcome. Transplantation. 1992;53(1):41-45.","journal-title":"Transplantation"},{"issue":"5","key":"ref12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1056\/NEJM199101313240505","article-title":"The effect of race on access and outcome in transplantation","volume":"324","author":"Kasiske","year":"1991","unstructured":"13.\tKasiske BL, Neylan JF, 3rd, Riggio RR, et al. The effect of race on access and outcome in transplantation. N Engl J Med. 1991;324(5):302-307.","journal-title":"N Engl J Med"},{"issue":"12","key":"ref13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJM199209173271203","article-title":"Overriding effects of HLA matching and socioeconomic factors","volume":"327","author":"Butkus","year":"1992","unstructured":"14.\tButkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors. N Engl J Med. 1992;327(12):840-845.","journal-title":"N Engl J Med"},{"issue":"2","key":"ref14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00000441-200202000-00002","article-title":"The epidemiology of end-stage renal disease among African Americans","volume":"323","author":"Martins","year":"2002","unstructured":"15.\tMartins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African Americans. Am J Med Sci. 2002;323(2):65-71.","journal-title":"Am J Med Sci"},{"issue":"2","key":"ref15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jama.1992.03480020057031","article-title":"Factors affecting the waiting time of cadaveric kidney transplant candidates in the United States","volume":"267","author":"Sanfilippo","year":"1992","unstructured":"16.\tSanfilippo FP, Vaughn WK, Peters TG, et al. Factors affecting the waiting time of cadaveric kidney transplant candidates in the United States. JAMA. 1992;267(2):247-252.","journal-title":"JAMA"},{"key":"ref16","volume-title":"Annual Report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network transplant data 1988\u20131997 Richmond","year":"1998","unstructured":"17.\tUnited Network for Organ Sharing. Annual Report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: transplant data: 1988\u20131997 Richmond, VA: United Network for Organ Sharing; 1998."},{"issue":"21","key":"ref17","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1056\/NEJM200011233432107","article-title":"Renal transplantation in black Americans","volume":"343","author":"CJ","year":"2000","unstructured":"18.\tYoung CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med. 2000;343(21):1545-1552.","journal-title":"N Engl J Med"},{"issue":"9","key":"ref18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved graft survival after renal transplantation in the United States, 1988 to 1996","volume":"342","author":"Hariharan","year":"2000","unstructured":"19.\tHariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605-612.","journal-title":"N Engl J Med"},{"issue":"5","key":"ref19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jamcollsurg.2007.01.024","article-title":"Racial disparities in renal allograft survival: a public health issue","volume":"204","author":"Eckhoff","year":"2007","unstructured":"20.\tEckhoff DE, Young CJ, Gaston RS, et al. Racial disparities in renal allograft survival: a public health issue? J Am Coll Surg. 2007;204(5):894-903.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"ref20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1600-6143.2005.01198.x","article-title":"Obesity and outcome following renal transplantation","volume":"6","author":"Gore","year":"2006","unstructured":"21.\tGore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6(2):357-363.","journal-title":"Am J Transplant"},{"issue":"6","key":"ref21","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/ndt\/gfl042","article-title":"Major effects of delayed graft function and cold ischaemia time on renal allograft survival","volume":"21","author":"Quiroga","year":"2006","unstructured":"22.\tQuiroga I, McShane P, Koo DD, et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant. 2006;21(6):1689-1696.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"ref22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/TP.0b013e318277438f","article-title":"Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression","volume":"95","author":"Narayanan","year":"2013","unstructured":"23.\tNarayanan M, Pankewycz O, El-Ghoroury M, et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. Transplantation. 2013;95(4):566-572.","journal-title":"Transplantation"},{"issue":"5","key":"ref23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1399-0012.2010.01343.x","article-title":"The relative risk of overall graft loss and acute rejection among African American renal transplant recipients is attenuated with advancing age","volume":"25","author":"Schold","year":"2011","unstructured":"24.\tSchold JD, Srinivas TR, Braun WE, Shoskes DA, Nurko S, Poggio ED. The relative risk of overall graft loss and acute rejection among African American renal transplant recipients is attenuated with advancing age. Clin Transplant. 2011;25(5):721-730.","journal-title":"Clin Transplant"},{"issue":"4","key":"ref24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/SLA.0000000000001385","article-title":"Racial Disparity in Renal Transplantation: Alemtuzumab the Great Equalizer","volume":"262","author":"Smith","year":"2015","unstructured":"25.\tSmith AA, John MM, Dortonne IS, et al. Racial Disparity in Renal Transplantation: Alemtuzumab the Great Equalizer? Ann Surg. 2015;262(4):669-674.","journal-title":"Ann Surg"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1681\/ASN.2013010049","article-title":"The effect of race and income on living kidney donation in the United States","volume":"24","author":"Gill","year":"2013","unstructured":"26.\tGill J, Dong J, Rose C, Johnston O, Landsberg D, Gill J. The effect of race and income on living kidney donation in the United States. J Am Soc Nephrol. 2013;24(11):1872-1879.","journal-title":"J Am Soc Nephrol"},{"issue":"5993","key":"ref26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","unstructured":"27.\tGenovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841-845.","journal-title":"Science"},{"issue":"3","key":"ref27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene","volume":"128","author":"Tzur","year":"2010","unstructured":"28.\tTzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128(3):345-350.","journal-title":"Hum Genet"},{"issue":"3","key":"ref28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1053\/j.ajkd.2015.04.046","article-title":"Testing for High-Risk APOL1 Alleles in Potential Living Kidney Donors","volume":"66","author":"LV","year":"2015","unstructured":"29.\tRiella LV, Sheridan AM. Testing for High-Risk APOL1 Alleles in Potential Living Kidney Donors. Am J Kidney Dis. 2015;66(3):396-401.","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"ref29","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","article-title":"APOL1 risk variants, race, and progression of chronic kidney disease","volume":"369","author":"Parsa","year":"2013","unstructured":"30.\tParsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183-2196.","journal-title":"N Engl J Med"},{"issue":"9","key":"ref30","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1681\/ASN.2013010113","article-title":"APOL1 variants associate with increased risk of CKD among African Americans","volume":"24","author":"Foster","year":"2013","unstructured":"31.\tFoster MC, Coresh J, Fornage M, et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol. 2013;24(9):1484-1491.","journal-title":"J Am Soc Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.\tLocke JE, Sawinski D, Reed RD, et al. Apolipoprotein L1 and chronic kidney disease risk in young potential living kidney donors. Ann Surg. 2017.  doi: 10.1097\/SLA.0000000000002174. [Epub ahead of print].","DOI":"10.1097\/SLA.0000000000002174"},{"issue":"7","key":"ref32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/01.tp.0000281942.97406.89","article-title":"Alemtuzumab induction in deceased donor kidney transplantation","volume":"84","author":"Huang","year":"2007","unstructured":"33.\tHuang E, Cho YW, Hayashi R, Bunnapradist S. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation. 2007;84(7):821-828.","journal-title":"Transplantation"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T07:40:27Z","timestamp":1554709227000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/archive\/2019\/17\/2\/0\/196\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2017.0065","relation":{},"ISSN":["1304-0855"],"issn-type":[{"value":"1304-0855","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}